How Automated ADC Filling Cuts Labor By 90%

Antibody-drug conjugates (ADCs) represent some of the most potent and high-value biologics in modern oncology pipelines, yet many manufacturers still rely on manual processes to handle these cytotoxic compounds. This case study examines how one Irish biopharmaceutical company confronted the inefficiencies and safety risks of manual ADC filling operations and evaluated a fully automated alternative.

Facing excessive operator hours, process variability, and contamination exposure risks across 10 batches per year totaling 1,000 liters of drug substance, the company benchmarked its existing workflow against Single Use Support's RoSS.FILL automated filling platform. The findings reveal a compelling case for automation; not only in terms of operator safety and sterility assurance, but also as a strategic financial decision with a return on investment achieved in under one year.